Grace Therapeutics, Inc. (GRCE) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -23.90M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 2.15M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-23.90M | (m) | (m) | $2.15M | (m) | (m) |
| 2026-03-31 | $-11.08M | (m) | (m) | $2.40M | (m) | (m) |
| 2025-12-31 | $-11.25M | (m) | (m) | $3.62M | (m) | (m) |
| 2025-09-30 | $-12.51M | (m) | (m) | $5.35M | (m) | (m) |
| 2025-06-30 | $-14.81M | (m) | (m) | $7.76M | (m) | (m) |
| 2025-03-31 | $-16.68M | (m) | (m) | $9.51M | (m) | (m) |
| 2024-12-31 | $-16.76M | (m) | (m) | $9.56M | (m) | (m) |
| 2024-09-30 | $-16.10M | (m) | (m) | $8.81M | (m) | (m) |
| 2024-06-30 | $-13.36M | (m) | (m) | $6.30M | (m) | (m) |
| 2024-03-31 | $-12.85M | (m) | (m) | $4.68M | (m) | (m) |
| 2023-12-31 | $-47.66M | (m) | (m) | $4.64M | (m) | (m) |
| 2023-09-30 | $-48.86M | (m) | (m) | $5.64M | (m) | (m) |
| 2023-06-30 | $-51.88M | (m) | (m) | $8.48M | (m) | (m) |
| 2023-03-31 | $-52.16M | (m) | (m) | $9.97M | (m) | (m) |
| 2022-12-31 | $-18.48M | (m) | (m) | $10.66M | (m) | (m) |
| 2022-09-30 | $-18.71M | (m) | (m) | $10.39M | (m) | (m) |
| 2022-06-30 | $-17.17M | (m) | (m) | $7.68M | (m) | (m) |
| 2022-03-31 | $-15.59M | (m) | $0.00 | $5.56M | (m) | (m) |
| 2021-12-31 | $-13.49M | (m) | $40.00K | $3.69M | (m) | (m) |
| 2021-09-30 | $-10.98M | (m) | (m) | $2.19M | (m) | (m) |
| 2021-06-30 | $-15.44M | (m) | (m) | $2.89M | (m) | (m) |
| 2021-03-31 | $-16.42M | (m) | $76.00K | $4.17M | (m) | (m) |
| 2020-12-31 | $-18.15M | (m) | (m) | $5.64M | (m) | (m) |
| 2020-09-30 | $-22.33M | (m) | (m) | $8.87M | (m) | (m) |
| 2020-06-30 | $-20.55M | (m) | (m) | $11.54M | (m) | (m) |
| 2020-03-31 | $-24.44M | (m) | (m) | $15.97M | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $-34.41M | (m) | (m) | $29.37M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |